A randomised, single centre, phase IV crossover study to assess the acceptability of once daily Zindaclin® used for one week compared to three other marketed topical antibiotics in patients with mild to moderate acne

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43187439

Enrollment

Registered

2005-10-06

Start date

2002-02-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate acne vulgaris. Skin and Connective Tissue Diseases Acne

Interventions

1. Zindaclin® once daily 2. Benzamycin® twice daily 3. Zineryt® twice daily 4. Dalacin-T® Topical Lotion twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male and female patients aged between 16 and 40 years with mild to moderate acne graded between 1.0 and 7.0 on the Leeds Revised Acne Grading System, 1998.

Exclusion criteria

Exclusion criteria: 1. Patients with acne conglobata, acne fulminans, sandpaper acne, submarine comedonal acne or secondary acne were excluded 2. The use of topical or systemic antibiotics or topical antimicrobials within the previous week was disallowed

Design outcomes

Primary

Measure	Time frame
Patient Acceptability Questionnaire assessing the four study products.	—

Secondary

Measure	Time frame
1. A conjoint analysis assessment of product preferences 2. The level of product use	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026